epoetin beta epoetin beta epoetin beta (inn), sold under the brand name neorecormon among others, is a synthetic, recombinant form of erythropoietin, a protein that promotes the production of red blood cells. it is an erythropoiesis-stimulating agent (esa) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. epoetin betaclinical datapronunciation/ɛˈpoʊ.ɪtɪn/ trade namesneorecormon, betapoietin, othersahfs/drugs.cominternational drug nameslicense data eu ema: by inn pregnancycategory au: b3 routes ofadministrationintravenous, subcutaneousatc codeb03xa01 (who) legal statuslegal status au: s4 (prescription only) eu: rx-only in general: ℞ (prescription only) identifierscas number122312-54-3 ndrugbankdb00016 ychemspidernoneunii64fs3bfh5wkeggd03232 n ny (what is this?) (verify) it is on the world health organization's list of essential medicines. chemistry epoetin beta is a recombinant form of human erythropoietin which is produced in chinese hamster ovary cells. it has the same protein sequence as natural human erythropoietin, being composed of 165 amino acids with about 30 kda molecular weight. history erythropoietin (epo) is a hormone produced in the kidneys. the existence of this hormone has been known since 1906, when scientists first started isolating it, and since the 1980s, a recombinant version of the hormone has been available for use in medical treatment.